Smith & Nephew (LON:SN) Insider Sells £243,274.57 in Stock

Key Points

• Deepak Nath, an insider at Smith & Nephew plc, sold 18,007 shares at an average price of GBX 1,351, totaling approximately £243,274.57.
• Smith & Nephew's current stock performance shows a market capitalization of £14.78 billion and a P/E ratio of 48.53, reflecting a relatively high valuation.
• Recent analyst ratings indicate a consensus rating of "Hold" for Smith & Nephew, with target prices ranging from GBX 1,300 to GBX 1,438, signaling mixed outlooks from brokerages.

Smith & Nephew plc (LON:SN - Get Free Report) insider Deepak Nath sold 18,007 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of GBX 1,351, for a total transaction of £243,274.57.

Smith & Nephew Stock Down 0.4%

Smith & Nephew stock traded down GBX 6 during mid-day trading on Friday, hitting GBX 1,385. The company's stock had a trading volume of 1,372,119 shares, compared to its average volume of 343,671. The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22. The firm has a market capitalization of £15.18 billion, a PE ratio of 49.87, a P/E/G ratio of 0.46 and a beta of 0.62. The firm's fifty day simple moving average is GBX 1,180.15 and its two-hundred day simple moving average is GBX 1,102.83.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on SN shares. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Smith & Nephew from GBX 1,300 to GBX 1,400 and gave the stock a "hold" rating in a research report on Wednesday, August 6th. Berenberg Bank lifted their target price on shares of Smith & Nephew from GBX 1,100 to GBX 1,300 and gave the company a "hold" rating in a research note on Thursday, August 7th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Smith & Nephew from GBX 1,357 to GBX 1,438 and gave the company an "overweight" rating in a research note on Wednesday, August 6th. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of GBX 1,379.33.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.